Skip to main content
. 2021 Oct 20;22(21):11342. doi: 10.3390/ijms222111342

Figure 4.

Figure 4

Dysmenorrhea rapidly decreased from severe at baseline to mild by week 8 and was sustained through to week 24. Error bars show the upper and lower limit of 95% confidence intervals; * p values compare relugolix combination therapy vs a placebo with respect to change in NRS dysmenorrhea defined previous page scores by week 24. CT = combination therapy; LS = least squares.